Top Markets
Coin of the day
IMBdx IMBdx

IMBdx

461030
Rank in Stocks #27702
IMBdx, Inc. specializes in developing advanced liquid biopsy technologies for... IMBdx, Inc. specializes in developing advanced liquid biopsy technologies for cancer detection and management. The company's core mission revolves around three key areas: facilitating the diagnosis and treatment strategies for advanced-stage cancers, enabling the early identification of cancer recurrence after surgical interventions, and providing solutions for the early diagnosis of cancer. Its notable product offerings include AlphaLiquid, CancerDetect, and CancerFind. The firm was established by Tae-Yu Kim, Sung-Tae Moon, and Doo-Hee Bang on July 5, 2018, and maintains its headquarters in Seoul, South Korea.
Share Price
$2.18
Market Cap
$31.27M
Change (1 day)
2.27%
Change (1 year)
-61.30%
Country
KR
Trade IMBdx (461030)

Category

Operating Margin for IMBdx (461030)
Operating Margin as of 2026 TTM: 0.00%
According to IMBdx latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for IMBdx from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
38.59% -
US
-149.01% -
US
28.81% -
NL
25.72% -
AU
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.